Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706833 | 0.87 | ALOX5AP (0.72) | ALOX5APADAMTS4CYP4F2CYP4A11 | |
| SCHEMBL706834 | 0.87 | ALOX5AP (0.72) | ALOX5APADAMTS4CYP4F2CYP4A11 | |
| SCHEMBL9924162 | 0.85 | ALOX5AP (0.51) | ALOX5AP | |
| SCHEMBL707244 | 0.82 | ALOX5AP (0.70) | ALOX5APADAMTS4MAPK14SMO | |
| SCHEMBL480223 | 0.79 | ALOX5AP (0.79) | ALOX5APADAMTS4MCL1MAPK14SMO | |
| SCHEMBL14396685 | 0.78 | ALOX5AP (0.48) | ALOX5APCYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL480396 | 0.77 | ALOX5AP (0.77) | ALOX5APADAMTS4MAPK14SMO | |
| SCHEMBL708385 | 0.77 | ALOX5AP (0.90) | ALOX5APSYKADAMTS4CYP4F2CYP4A11 | |
| SCHEMBL708386 | 0.77 | ALOX5AP (0.90) | ALOX5APSYKADAMTS4CYP4F2CYP4A11 | |
| SCHEMBL708933 | 0.77 | ALOX5AP (0.48) | ALOX5APMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149674-A1 | Diaryl Substituted Alkanes | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885SYK 3335/4885ADAMTS4 1701/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885SYK 3335/4885ADAMTS4 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.